Immunovant, Inc. (IMVT) Form 8-K — Nov 9, 2026
Immunovant reported fiscal Q2 2026 results and clinical updates on November 9, 2026, anchored by positive Phase 2 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis. In the randomized withdrawal Period 2 of the potentially registrational D2T RA trial, the 600 mg dose met the primary ACR20 endpoint (92.5% vs 75.6% placebo, p=0.0139), with exploratory ACR50 of 80.0% and ACR70 of 52.5%. The 300 mg dose showed no separation from placebo, and FDA discussions are planned for later this year on the registrational path.
Key figures
- Revenue
- 0
- Cash Position
- 722300000
- Shares Outstanding
- 206785540
- Acr20 600mg
- 92.5%
- Acr50 600mg
- 80.0%
- Acr70 600mg
- 52.5%
- Acr20 placebo
- 75.6%
- Q2 ga expense
- 19144000
- Q2 rnd expense
- 85011000
- Q2 non gaap net loss
- 83965000
- Primary endpoint pvalue
- 0.0139
- Q2 rnd expense prior year
- 114249000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.